PURPOSE: Relatively few studies have focused on T4N2 (stage IIIB) locally advanced @entity1149 ( @entity1149 ). In this study, we tried to identify prognostic factors for @entity1 with clinical stage T4N2 @entity1149 . METHODS: We retrospectively identified 223 @entity1 , of which 168 met the inclusion criteria. @entity1 treated with curative intent using concurrent chemoradiotherapy (CRT) with or without adjuvant chemotherapy, or concurrent CRT after induction chemotherapy, were included in this study. Relevant @entity1 , treatment, and disease factors were evaluated for their prognostic significance in both univariate and multivariate analyses using the Cox proportional hazards model. RESULTS: The median progression-free survival (PFS) was 13 months (95% confidence interval [CI], 10.6-15.4). The median @entity1349 ( @entity1349 ) was 20 months (95% CI, 16.8-23.1), and 71, 40.3 and 28.2% of the @entity1 survived for 1, 2 and 3 years after diagnosis, respectively. Multivariate analysis showed Eastern Cooperative Oncology Group (ECOG) performance status (PS) was independent predictor of PFS (hazard ratio [HR], 0.24; 95% CI, 0.13-0.43; p=0.001), and @entity1349 [HR, 0.48; 95% CI, 0.26-0.87; p=0.015). Absence of multifocal T4 @entity5 was also associated with a significantly longer @entity1349 (HR, 046; 95% CI, 0.31-0.7; p=0.001). There was no statistically significant difference in @entity1349 and PFS between treatment modalities. CONCLUSION: PFS and @entity1349 were significantly shorter in @entity1 with poor ECOG PS. @entity1349 was also significantly shorter in @entity1 with multifocal T4 @entity5 . There were no differences between the two therapeutic approaches with respect to outcome.

Prognostic factors in clinical stage T4N2 locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
